IP Library Granted Patent US 9,884,084
Granted Patent B2
US 9,884,084 · App. 14/401,408 · Granted Feb 6, 2018

Bone loss preventing and bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide

Inventors: Seung Hyun Han (Seoul, KR); Ok-Jin Park (Seoul, KR); Cheol-Heui Yun (Seoul, KR)
Assignee: SNU R&DB FOUNDATION
A61K38/05A23L33/18A23V2002/00A61K2039/5555A61K2039/6062
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,084
App. No.
14/401,408
Granted
Feb 6, 2018
Kind
B2
Abstract

The present invention relates to a bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide, an analog thereof, a derivative thereof or a pharmaceutically acceptable salt thereof. In contrast to existing passive therapeutic agents which center on bone absorption suppression based on mechanisms for reducing osteoclast functionality, the composition comprising muramyl dipeptide of the present invention promotes the differentiation of osteoblasts, which are bone forming cells, and can advantageously be used in various diseases where bone formation is required as an active therapeutic agent that does not affect osteoclast.

Claims (4)

1. A method of improving or treating a bone disorder in a subject in need thereof by reducing bone loss or promoting bone regeneration or formation, the method comprising administering to the subject a composition consisting of an effective amount of a muramyl-dipeptide or a muramyl-dipeptide derivative selected from the group consisting of N-acetylmuramyl-L-alanine-D-isoglutamine-lysine, 6-O-stearoyl-N-acetylmuramyl-L-alanine-D-isoglutamine, acetylglucosamine-N-acetylmuramyl-L-alanine-D-isoglutamine and acetylglucosamine-N-acetylmuramyl-L-alanine-D-isoglutamine-lysine, or a pharmaceutically acceptable salt thereof, wherein the bone disorder are osteoporosis, bone damage caused by bone metastasis of cancer cells, osteomalacia, rickets, adynamic bone disease, metabolic bone disease, osteolysis, bone deformity, osteoarthritis, deformity correction, dental correction, bone fracture treatment, osteosynthesis, bone regeneration of false joints, bone formation, and bone grafting.

2. The method of claim 1 , wherein the muramyl-dipeptide is N-acetylmuramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine, N-acetylmuramyl-L-valyl-D-isoglutamine, or N-acetylmuramyl-L-seryl-D-isoglutamine.

3. The method of claim 1 , wherein the composition is a pharmaceutical composition, a health food supplement, or a health functional food or a food additive.

4. The method of claim 1 , wherein the osteoporosis is primary osteoporosis or secondary osteoporosis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2020
From: SNU R&DB FOUNDATION
To: HYSENSBIO
Reel/Frame 054166/0191 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE THIRD ASSIGNOR PREVIOUSLY RECORDED AT REEL: 034176 FRAME: 0719. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 3, 2016
From: HAN, SEUNG HYUN; PARK, OK-JIN; YUN, CHEOL-HEUI
To: SNU R&DB FOUNDATION
Reel/Frame 037981/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2014
From: HAN, SEUNG HYUN; PARK, OK-JIN; YUN, CHEOL-HEUL
To: SNU R&DB FOUNDATION
Reel/Frame 034176/0719 →
Priority Claims (1)
KR 10-2012-0051837 · May 16, 2012 · national
Continuity (1)
Related Publication 20150141352A1 · May 21, 2015